Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures

Mash, Deborah C., Kovera, Craig A., Pablo, John, Tyndale, Rachel F., Ervin, Frank D., Williams, Izben C., Singleton, Edward G., Mayor, Manny · 2000 · Annals of the New York Academy of Sciences

AI-extracted · unverified · confirm at source

Preliminary efficacy (n=27, 500–800 mg ibogaine HCl): BDI depression scores fell significantly (16.86→2.29, p=.0005). Opiate craving reduced across all 5 HCQN-29 subscales (p<.0001). Cocaine craving reduced on 3 of 5 CCQN-45 subscales.

Dosing: 500, 600, or 800 mg fixed-dose oral ibogaine HCl (human) (oral)

Sample size: 27

Contraindications: histories of stroke, epilepsy, axis I psychotic disorders